ReviewPharmaceutical research2007
Micellar nanocarriers: pharmaceutical perspectives.
Review in Pharmaceutical research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 422 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
422 citing papers in PubMed.
- Overcoming the nuclear barrier in nonviral gene therapy: mechanisms, carrier design, and translational perspectives on NLS peptide and DNA targeting sequence strategies.Drug delivery · 2026Review
- Beyond Nanosizing: Mechanism-Guided Design and Rational Selection of Polymeric and Lipid Nanocarriers for Translatable Drug Delivery.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Exploring Novel Strategies for Improving the Bioavailability of Docetaxel.AAPS PharmSciTech · 2026Review
- Thermoresponsive Nanogel IncorporatingACS omega · 2026Article
- TPGS-stabilized pyrimethamine micelles promote ROS-associated apoptosis in MDA-MB-231 cells and suppress tumour progression in a murine lymphoma model.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Bridging the Lab-to-Clinic Gap in Intranasal Nanomaterial-Based Chemotherapy for Glioblastoma.Pharmaceutics · 2026Review
- A Non-Antigenic Randomized Polyethylene Glycol/Poly(2-Phenyl-2-Oxazine)-Based Drug Delivery Platform.Macromolecular rapid communications · 2026Article
- Physicochemical Aspects of Mixed Micelle Formation Between Amphiphilic Drugs and Surfactants.International journal of molecular sciences · 2026Review
- Radiolabelled ZnO, Iron Oxide-Based, and Gold Nanoparticles for Cancer Therapy: Synthesis, Surface Engineering, and Radiolabelling Strategies.International journal of molecular sciences · 2026Review
- Comparative Study of Fisetin-Loaded Poloxamer 407 and Poloxamer 188 Mixed Micelles as Nanocarrier Systems.Molecules (Basel, Switzerland) · 2026Article
- Bridging the Gap in the Clinical Application of Advanced Parenteral Nutrition Formulations: From Efficacy to Real-World Challenges.Advances in nutrition (Bethesda, Md.) · 2026Review
- Ex Vivo Buccal Permeability of Nanostructured Lipid Carriers (NLCs) Associated with a Peptide Drug Model.Pharmaceutics · 2026Article
- Adsorption of Mixed Micelles of Polysorbate 80 and Oleic Acid to the Air-Water Interface.Langmuir : the ACS journal of surfaces and colloids · 2026Article
- Nanoparticle Drug Delivery Systems: The Future Direction for the Treatment of Tumors.International journal of nanomedicine · 2026Review
- Exploring the Therapeutic Potential of Nanocarrier-Mediated Drug Delivery in Rheumatoid Arthritis (RA) Treatment.Current rheumatology reviews · 2026Review
- Advances in phytochemical-derived nanotherapeutics for multimodal eradication of multidrug-resistantFrontiers in pharmacology · 2026Review
- Nanobody-Based Drug Delivery: Emerging Strategies for Targeted Cancer Therapy.International journal of nanomedicine · 2026Review
- Enhanced anticancer efficacy of α-lipoic acid-loaded TPGS micelles: Synthesis, characterization, and evaluation in a 4T1 breast cancer model.BioImpacts : BI · 2026Article
- Novel Spontaneous Nanoemulsions for Phosphorus Selenide Compounds: Toward Enhanced Solubility and Stable Aqueous Formulations.ACS omega · 2025Article
- Fabrication of PAA-RSC advances · 2025Article
362 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Micelles, self-assembling nanosized colloidal particles with a hydrophobic core and hydrophilic shell are currently successfully used as pharmaceutical carriers for water-insoluble drugs and demonstrate a series of attractive properties as drug carriers. Among the micelle-forming compounds, amphiphilic copolymers, i.e., polymers consisting of hydrophobic block and hydrophilic block, are gaining an increasing attention. Polymeric micelles possess high stability both in vitro and in vivo and good biocompatibility, and can solubilize a broad variety of poorly soluble pharmaceuticals many of these drug-loaded micelles are currently at different stages of preclinical and clinical trials. Among polymeric micelles, a special group is formed by lipid-core micelles, i.e., micelles formed by conjugates of soluble copolymers with lipids (such as polyethylene glycol-phosphatidyl ethanolamine conjugate, PEG-PE). Polymeric micelles, including lipid-core micelles, carrying various reporter (contrast) groups may become the imaging agents of choice in different imaging modalities. All these micelles can also be used as targeted drug delivery systems. The targeting can be achieved via the enhanced permeability and retention (EPR) effect (into the areas with the compromised vasculature), by making micelles of stimuli-responsive amphiphilic block-copolymers, or by attaching specific targeting ligand molecules to the micelle surface. Immunomicelles prepared by coupling monoclonal antibody molecules to p-nitrophenylcarbonyl groups on the water-exposed termini of the micelle corona-forming blocks demonstrate high binding specificity and targetability. This review will discuss some recent trends in using micelles as pharmaceutical carriers.
Indexed as
Identifiers
17109211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.